| 000 | 01882 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250518015855.0 | ||
| 264 | 0 | _c20190503 | |
| 008 | 201905s 0 0 eng d | ||
| 022 | _a1878-3511 | ||
| 024 | 7 |
_a10.1016/j.ijid.2019.01.002 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLescuyer, Sylvain | |
| 245 | 0 | 0 |
_aTuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera. _h[electronic resource] |
| 260 |
_bInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases _cMar 2019 |
||
| 300 |
_a134-136 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMycobacterium Infections, Nontuberculous _xdrug therapy |
| 650 | 0 | 4 |
_aMycobacterium avium _xdrug effects |
| 650 | 0 | 4 |
_aMycobacterium tuberculosis _xdrug effects |
| 650 | 0 | 4 | _aNitriles |
| 650 | 0 | 4 |
_aPolycythemia Vera _xdrug therapy |
| 650 | 0 | 4 |
_aPrimary Myelofibrosis _xdrug therapy |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aPyrazoles _xtherapeutic use |
| 650 | 0 | 4 | _aPyrimidines |
| 650 | 0 | 4 |
_aTuberculosis _xdrug therapy |
| 700 | 1 | _aLedoux, Marie-Pierre | |
| 700 | 1 | _aGravier, Simon | |
| 700 | 1 | _aNatarajan-Amé, Shanti | |
| 700 | 1 | _aDuval, Céline | |
| 700 | 1 | _aMaloisel, Fréderic | |
| 700 | 1 | _aMauvieux, Laurent | |
| 700 | 1 | _aToussaint, Elise | |
| 700 | 1 | _aFornecker, Luc-Matthieu | |
| 700 | 1 | _aHerbrecht, Raoul | |
| 773 | 0 |
_tInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases _gvol. 80 _gp. 134-136 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ijid.2019.01.002 _zAvailable from publisher's website |
| 999 |
_c29250734 _d29250734 |
||